Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication

Abstract

Early detection and diagnosis are the key to successful clinical management of pancreatic cancer and improve the patient outcome. However, due to the absence of early symptoms and the aggressiveness of pancreatic cancer, its 5-year survival rate remains below 5 %. Compared to tissue samples, liquid biopsies are of particular interest in clinical settings with respect to minimal invasiveness, repeated sampling, complete representation of the entire or multi-site tumor bulks. The potential of liquid biopsies in pancreatic cancer has been demonstrated by many studies which prove that liquid biopsies are able to detect early emergency of pancreatic cancer cells, residual disease, and recurrence. More interestingly, they show potential to delineate the heterogeneity, spatial and temporal, of pancreatic cancer. However, the performance of liquid biopsies for the diagnosis varies largely across different studies depending of the technique employed and also the type and stage of the tumor. One approach to improve the detect performance of liquid biopsies is to intensively inspect circulome and to define integrated biomarkers which simultaneously profile circulating tumor cells and DNA, extracellular vesicles, and circulating DNA, or cell free DNA and proteins. Moreover, the diagnostic validity and accuracy of liquid biopsies still need to be comprehensively demonstrated and validated.

Burn Injury Induces Proinflammatory Plasma Extracellular Vesicles That Associate with Length of Hospital Stay in Women: CRP and SAA1 as Potential Prognostic Indicators

“…In addition to their protein cargo, EVs contain a diverse profile of miRNAs that have been used in a various disease settings such as pancreatic cancer in attempts to identify potential biomarkers [ 31 ]. Therefore, we isolated miRNAs in plasma EVs from the same patients that were assessed for protein changes by LC-MS/MS using the human miRNA panel v2.…”

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

“…It is true that liquid biopsy is one of the main focuses of attention in current research, with the aim to apply it to the biomedical field. It is known that, compared to tissue samples, liquid biopsies are of particular interest in clinical settings due to their minimal invasiveness since they provide the opportunity to repeat sampling, as well as to have a whole representation of the entire tumor [57]. Liquid biopsies could be a relevant point when there is limited access to the tissue biopsy, giving increasing advantages in precision medicine for direct biomarker application in clinical practice [58].…”

Screening and Validation of Independent Predictors of Poor Survival in Pancreatic Cancer

“…With the advent of the era of big data, a variety of tumor-related public databases have sprung up, which provides a large amount of genomic data and its corresponding clinical data for oncology basic medicine and translational medicine. Over the last decades, public databases, including the well-known The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) database, etc., have been widely applied in screening of the molecular mechanisms of PC, which could provide powerful support for identification of effective and accurate prognosis predictors of PC patients [ 3 , 4 ].…”